$4.9 B

LOXO Mkt cap, 20-Sep-2018
Loxo Oncology Net income (Q2, 2018)-15.3 M
Loxo Oncology EBIT (Q2, 2018)-20.5 M
Loxo Oncology Cash, 30-Jun-2018147.7 M

Loxo Oncology Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016

R&D expense

323 k14 m58.3 m

General and administrative expense

583 k10.5 m14.9 m

Operating expense total

906 k24.5 m73.2 m

Net Income

(10.3 m)(35.9 m)(72.4 m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

R&D expense

2.8 m3.4 m8.4 m12.3 m14.2 m20.2 m24.4 m32 m73.5 m

General and administrative expense

2.4 m2.6 m3.4 m3.8 m3.7 m4.8 m6.5 m12.2 m27.9 m

Operating expense total

5.2 m5.9 m11.8 m16.1 m17.9 m24.9 m30.9 m44.2 m101.5 m

EBIT

(5.8 m)(20.5 m)

Interest income

2.2 m5.2 m

Net Income

(8.1 m)(8.8 m)(11.6 m)(15.9 m)(17.7 m)(24.5 m)(30.4 m)(3.6 m)(15.3 m)

Loxo Oncology Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016

Cash

43.9 m68.2 m30.4 m

Accounts Receivable

1.1 b

Current Assets

107.8 m156.6 m141.8 m

PP&E

12 k88 k248 k

Total Assets

114.5 m157.5 m145.3 m

Accounts Payable

239 k269 k1.1 m

Total Liabilities

15.1 m

Additional Paid-in Capital

143.7 m221.5 m269.4 m

Retained Earnings

(31 m)(66.8 m)(139.2 m)

Total Equity

112.7 m154.6 m130.2 m

Financial Leverage

1 x1 x1.1 x

Quarterly

USDQ1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

48.5 m260.3 m103.8 m147.7 m

Current Assets

244.4 m471.4 m720.6 m676.7 m

PP&E

328 k364 k1.6 m3.3 m

Total Assets

249.4 m472.4 m748.6 m716.5 m

Accounts Payable

1.3 m2.2 m5.8 m4.8 m

Current Liabilities

204.5 m185.9 m

Total Liabilities

10.4 m11.2 m364.2 m324.4 m

Additional Paid-in Capital

402.9 m655.6 m676.8 m696 m

Retained Earnings

(163.8 m)(194.2 m)(291.7 m)(303.4 m)

Total Equity

239 m461.3 m384.4 m392.1 m

Financial Leverage

1 x1 x1.9 x1.8 x

Loxo Oncology Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016

Net Income

(20.7 m)(35.9 m)(72.4 m)

Depreciation and Amortization

1 k17 k77 k

Accounts Payable

18 k30 k792 k

Cash From Operating Activities

(2.8 m)(30.2 m)(51.3 m)

Purchases of PP&E

(14 k)(93 k)(237 k)

Cash From Investing Activities

(69.1 m)(17.2 m)(26.5 m)

Cash From Financing Activities

115.7 m71.6 m40 m

Quarterly

USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(8.1 m)(8.8 m)(11.6 m)(15.9 m)(17.7 m)(24.5 m)(54.9 m)(3.6 m)(15.3 m)

Depreciation and Amortization

21 k48 k80 k186 k

Accounts Payable

207 k285 k415 k731 k758 k677 k1 m192 k1.1 m1.8 m793 k

Cash From Operating Activities

(26.7 m)(50.5 m)109.8 m74.8 m

Purchases of PP&E

(101 k)(164 k)(746 k)(2.6 m)

Cash From Investing Activities

(84.7 m)(96.3 m)(148.2 m)(76.3 m)

Cash From Financing Activities

129.5 m376.7 m229 k7.1 m

Loxo Oncology Ratios

USDY, 2018

Financial Leverage

1.8 x
Report incorrect company information